Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive headline results had been announced earlier. ORY-1001’s further development is now in Roche’s hands, which also initiated a Phase I trial in a new indication small cell lung cancer (SCLC). Recently Oryzon released preclinical data supporting ORY-2001’s potential in multiple sclerosis (MS), which we now include in our valuation. All these developments led to an increase in our Oryzon’s valuation to €250m.
ASH data provide more granularity; SCLC in Phase I
While most of the positive share price-moving ORY-1001 Phase I/IIa data had already been released in the form of an abstract, more details were provided in the poster session at ASH annual meeting on 3 to 6 December 2016. Development of ORY-1001 is now in the hands of Roche, which indicated that a potential path forward in acute leukaemia could be a combination regimen with ORY-1001. Another positive development was the initiation of the Phase I trial in SCLC, which is in line with our expectations.
To read the entire report Please click on the pdf File Below